Content deleted Content added
Line 183:
2. Add "and neuromuscular" after "neurological" in the first sentence, since the company has added a therapy for oculopharyngeal muscular dystrophy<ref name=Carroll070918>{{cite news|last1=Carroll|first1=John|title=Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal|url=https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/|newspaper=Endpoints|date=9 July 2018}}</ref>, a neuromuscular disease<ref>{{cite web|title=Oculopharyngeal Muscular Dystrophy|url=https://rarediseases.org/rare-diseases/oculopharyngeal-muscular-dystrophy/|publisher=National Organization for Rare Diseases|date=2012}}</ref>, to its pipeline
3. Change the second sentence in the fourth paragraph from "As of 2016 Axovant was developing it as a treatment for Lewy body dementia" to "Axovant was developing it as a treatment for [[Lewy body dementia]]<ref name=Grover042818>{{cite web |title=Acadia drug approval could clear way for Axovant dementia therapy |author=Grover, Natalie |date=28 Apr 2016 |website=Reuters |url=https://www.reuters.com/article/us-axovant-sciences-dementia-idUSKCN0XP2IL }}</ref>, but discontinued its development following the completion of a clinical trial that did not meet its primary endpoint<ref name=Taylor121018>{{cite news|last1=Taylor|first1=Nick Paul|title=Axovant dumps nelotanserin in retreat from small molecule R&D|url=https://www.fiercebiotech.com/biotech/axovant-dumps-nelotanserin-retreat-from-small-molecule-r-d|newspaper=FierceBiotech|date=10 December 2018}}</ref><ref name=Terry121018>{{cite news|last1=Terry|first1=Mark|title=Axovant Abandons Another Dementia Drug After Failed Trial|url=https://www.biospace.com/article/axovant-abandons-another-dementia-drug-after-failed-trial/|newspaper=BioSpace|date=10 December 2018}}</ref>."
4. Following the last paragraph, add "Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018<ref>{{cite news|last1=Terry|first1=Mark|title=Axovant Licenses Gene Therapy for Parkinson’s Disease from Oxford BioMedica|url=https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/|newspaper=BioSpace|date=6 June 2018}}</ref><ref>{{cite news|last1=Garde|first1=Damian|title=Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy|url=https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/|newspaper=STAT'' News|date=6 June 2018}}</ref>. In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.<ref name="Carroll070918" /> In December 2018, Axovant added two additional gene therapy programs to treat GM1 gangliosidosis and Tay-Sachs and Sandhoff diseases <ref name="Keown121418" /><ref name="Taylor121418" />.”
| |||